Endoskeleton interbody devices; Image courtesy of Titan Spine
Titan Spine reported +49% year-over-year sales growth at the end of 2Q17, driven by increased demand for its nanoLOCK® surface technology. Sequentially, nanoLOCK sales grew +42% from 1Q17.
Since 4Q16 launch, nanoLOCK has been implanted 2,500 times by 150 surgeons in nearly 100 hospitals. This represents a doubling of surgeon nanoLOCK users in 2Q vs. 1Q17. The company has invested capital in increased inventory of implants and instruments to meet demand.
Titan Spine’s annual sales grew nearly 50% in 2015 and 2016, according to ORTHOWORLD estimates. For 2016, ORTHOWORLD estimated company sales in a range from $50.0MM to $53.0MM. If growth continues on its present path, we estimate that 2017 sales could surpass $72.0MM.
The strong growth is partially attributed to Titan Spine’s ability to expand its surgeon reach by doubling its workforce, as well as its efforts to demonstrate nanoLOCK’s effectiveness—backing it with data, warranties and clinical codes.
nanoLOCK features a micro- and nano-scaled architecture designed to improve the osteogenic response and support fusion. Within 2016, CMS created a new technology ICD-10 code for a nanotextured surface on an interbody fusion device. Titan Spine’s nanoLOCK surface technology has access to use this code. Further, the company’s Endoskeleton® interbody fusion devices, which feature nanoLOCK, are covered by a risk share warranty that provides a free replacement if any Endoskeleton interbody fusion device delaminates or geneates particulate debris during implantation.
Titan Spine reported +49% year-over-year sales growth at the end of 2Q17, driven by increased demand for its nanoLOCK® surface technology. Sequentially, nanoLOCK sales grew +42% from 1Q17.
Since 4Q16 launch, nanoLOCK has been implanted 2,500 times by 150 surgeons in nearly 100 hospitals. This represents a doubling of surgeon nanoLOCK users in...
Endoskeleton interbody devices; Image courtesy of Titan Spine
Titan Spine reported +49% year-over-year sales growth at the end of 2Q17, driven by increased demand for its nanoLOCK® surface technology. Sequentially, nanoLOCK sales grew +42% from 1Q17.
Since 4Q16 launch, nanoLOCK has been implanted 2,500 times by 150 surgeons in nearly 100 hospitals. This represents a doubling of surgeon nanoLOCK users in 2Q vs. 1Q17. The company has invested capital in increased inventory of implants and instruments to meet demand.
Titan Spine’s annual sales grew nearly 50% in 2015 and 2016, according to ORTHOWORLD estimates. For 2016, ORTHOWORLD estimated company sales in a range from $50.0MM to $53.0MM. If growth continues on its present path, we estimate that 2017 sales could surpass $72.0MM.
The strong growth is partially attributed to Titan Spine’s ability to expand its surgeon reach by doubling its workforce, as well as its efforts to demonstrate nanoLOCK’s effectiveness—backing it with data, warranties and clinical codes.
nanoLOCK features a micro- and nano-scaled architecture designed to improve the osteogenic response and support fusion. Within 2016, CMS created a new technology ICD-10 code for a nanotextured surface on an interbody fusion device. Titan Spine’s nanoLOCK surface technology has access to use this code. Further, the company’s Endoskeleton® interbody fusion devices, which feature nanoLOCK, are covered by a risk share warranty that provides a free replacement if any Endoskeleton interbody fusion device delaminates or geneates particulate debris during implantation.
Copy to clipboard 
